Dianthus Therapeutics Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
to go through a few slides with a quick overview of Dianthus, then we will get into a Q&A.
Thank you, Alex, and thank you to you and the Stifel team for this opportunity to update everyone on what is going on at Dianthus. Just quickly, I will be making some forward-looking statements, so I urge everybody to go to our website and read our SEC filings for all the appropriate risks around investing in Dianthus. I am just going to do a very quick overview of claseprubart and set the frame the conversation we are very likely to have, especially around MMN. Our goal here for claseprubart is to achieve a target product profile that would position claseprubart as a preferred first-line treatment across all three indications we are pursuing, MG, CIDP, and MMN. What does that mean? Well, first, we are aiming for best in disease efficacy, and I will get into a moment how we will position the product that way.
We are looking for differentiated safety as being the only complement inhibitor potentially in these markets without a box warning or a REMS program. Then, of course, delivering it in the DUPIXENT auto-injector, essentially, a 300 milligram, two milliliter shot once a month in MG, once every two weeks in CIDP and MMN. We see this as a huge opportunity where you look at all three indications together, we are looking at over 150,000 patients, with MMN being severely underdiagnosed and with the potential to really grow that market with more effective therapies being launched. I mentioned we are looking for best in disease efficacy. What gives us the confidence that we potentially could have that? On the left here, you see how we would differentiate versus C5s in the MG space.
With claseprubart being an active C1s inhibitor, a classical pathway inhibitor, an upstream inhibitor within the complement system, what we will be able to do that C5s cannot is prevent the formation of C3a and the deposition of C3b. These are toxic pro-inflammatory split products that are a result of the complement cascade and all occur before C5s interrupt the complement cascade. These are causing inflammation and damage at the neuromuscular junction for MG patients, and we will be able to prevent that. We believe that will result in a higher MG ADL potentially versus C5s. This is the reason an active C1s inhibitor works in CIDP and MMN, and a C5 will not, because these are the pro-inflammatory toxic byproducts of the complement cascade that cause the damage in CIDP and MMN.
On the right, middle and right, you see how we compare to two complement inhibitors in development for CIDP and MMN. riliprubart, you see we have seven times more potency than riliprubart. Versus empasiprubart in the same in vitro experiment they conducted in their own publication published last year, the Quidel MicroVue CH50, at the IC90, we are 38 times more potent. We believe, at least in CIDP, it looks like we have better efficacy versus riliprubart, and we will have to see versus empasiprubart once they have their phase III data in MMN, and we have our phase III data in MMN. Speaking of MMN, we are expecting data from our phase II in December. A reminder, this is a very small study, originally planned to have only 12 patients per arm.
In 2024, when we went to see the FDA, we would have loved to just go straight into a phase III, the way we did with CIDP, because it will be a supplementary BLA. There was really no precedent for what a phase III trial would look like in this space, so we decided to do a small proof of concept phase II study. We over-enrolled, which is great, so we will have about 15 patients per arm. We are testing 300 milligrams every two weeks and 600 milligrams every two weeks. We do not expect to see any efficacy difference between those two doses. Primarily, it is a safety study. I can tell you on a blinded basis, the data looks very similar to MG and CIDP, so we are very confident on that front.
Secondary endpoints will be things like grip strength, which we now know is the primary endpoint in a phase III study. When we reveal our results, people will want to compare, of course, to ARDA, the phase II study from argenx with empasiprubart. I will just caution that there is one major difference between our study, the phase II study, and their phase II study. They made a big deal out of their 91% reduction in required retreatment with IVIG to rescue patients. Our protocols are very different on that point. In our trial, a patient has to relapse, has to have a documented clinical deterioration to get IVIG. Every patient who did have a clinical deterioration gets IVIG. If you did not relapse, you do not get IVIG, period. Very simple, and it makes sense. That is our protocol. The protocol for ARDA, there are patients who clinically deteriorate and did not get IVIG.
There are patients who did not clinically deteriorate, but raised their hand and asked for it and got it. It is a very, very different protocol, and therefore it is not going to be possible to compare on IVIG retreatment. What I would say is safety is fair to compare, and then the secondary endpoint on grip strength, very similar. We have a three-day average grip strength, as they did in phase II. That is fair to compare. Then just basically relapse rates. That is a fair comparison. IVIG retreatment, we have completely different protocols and not going to be able to compare. Finally, just how do we compare in a bigger picture? How does claseprubart compare to empasiprubart? empasiprubart is a C2 inhibitor.
As you saw on the potency slide, we are much more potent in terms of shutting down the classical pathway using the assay they published with, the assay that they used to highlight their potency. We are 38 times more potent. They block the lectin pathway and the classical pathway. There is no way for the complement system to really react to the presence of encapsulated bacteria if you are shutting down both those pathways. We leave the lectin and alternate pathways intact. The lectin pathway is the main pathway that will be triggered by the presence of encapsulated bacteria. That will then rev up the alternate pathway, that will rev up the formation of MAC, and then goes and lyses the bacteria. That is what protects you from, for example, meningococcal infections. We leave the lectin alternate pathways intact to be able to do that.
It is very likely they will end up with a box warning and a REMS program. Then finally, they are an IV, and we are a subcu, self-administered auto-injector every two weeks. The exact same one as DUPIXENT. Go to the DUPIXENT patient website, see how easy it is. That is what we are going to launch with.
Thank you. Great. Thanks, Marino.
Maybe since we are talking about MMN, I kind of want to maybe start with a question around, obviously, the focus for you of the phase II study is a safety study, right? You will get some endpoints around efficacy. How are you thinking about what signals you might be able to see, and how does that impact your thoughts around moving into a pivotal study after this readout?
We are going to be looking at the same secondary endpoints in terms of muscle strength as argenx did with their ARDA study.
Now we know that grip strength is going to be the primary endpoint in phase III. So those are going to be fair to look at. What we're looking for is very similar to ARDA, just numerical trends.
I'll be honest with you, there's almost nothing that we will see in our phase II study will keep us from going into a phase III study. We know MMN is IgM driven. We know that it's triggering the classical pathway. argenx and Dianthus are 100% aligned on that it's a classical pathway-driven disease, and we shut down the classical pathway with one shot every two weeks.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
